View Item 

Show simple item record

The comparative biology of skeletal metastasis
dc.contributor.authorLester, P. A.en_US
dc.contributor.authorKeller, Evan T.en_US
dc.date.accessioned2010-06-01T20:16:14Z
dc.date.available2010-06-01T20:16:14Z
dc.date.issued2003-09en_US
dc.identifier.citationLester, P. A.; Keller, E. T. (2003). "The comparative biology of skeletal metastasis." Veterinary and Comparative Oncology 1(3): 131-139. <http://hdl.handle.net/2027.42/73390>en_US
dc.identifier.issn1476-5810en_US
dc.identifier.issn1476-5829en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73390
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19379312&dopt=citationen_US
dc.description.abstractBone metastasis, a very common sequelae of cancer, is often associated with great morbidity. Understanding the biology of bone metastases may lead to therapeutic interventions to target the metastases. In addition to replacing bone marrow elements, the presence of tumour cells in bone modulates the normal bone remodelling process. Some tumours result in primarily osteolytic bone lesions, whereas others are associated with osteoblastic bone lesions. In either case, the resulting changes in the bone structure result in weakened bone that induces pain and is predisposed to fracture. The mechanisms through which cancer cells modulate bone remodelling are not clearly defined, but ongoing research using a variety of animal models will hopefully provide clues to prevent or slow the progress of bone metastases.en_US
dc.format.extent1693537 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rightsBlackwell Publishing Ltd., 2003en_US
dc.subject.otherBMPen_US
dc.subject.otherCanceren_US
dc.subject.otherMetastasisen_US
dc.subject.otherOsteoblasten_US
dc.subject.otherOsteoclasten_US
dc.subject.otherProstateen_US
dc.subject.otherRANKLen_US
dc.titleThe comparative biology of skeletal metastasisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUnit for Laboratory Animal Medicine and Department of Pathology, School of Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.identifier.pmid19379312en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73390/1/j.1476-5829.2003.00023.x.pdf
dc.identifier.doi10.1111/j.1476-5829.2003.00023.xen_US
dc.identifier.sourceVeterinary and Comparative Oncologyen_US
dc.identifier.citedreferenceAkatsu T., Ono K., Murakami T., Katayama Y., Nishikawa M., Wada S., Yamamoto M., Kugai N., Matsuura N., Takada Y. & Nagata N. ( 1998 ) Chinese hamster ovary cells expressing α4β1 integrin stimulate osteoclast formation in vitro. Journal of Bone and Mineral Research, 13: 1251 – 9.en_US
dc.identifier.citedreferenceAlsina M., Guise T. A. & Roodman G. D. ( 1996 ) Cytokine regulation of bone cell differentiation. Vitamins and Hormones, 52: 63 – 98.en_US
dc.identifier.citedreferenceArai C., Ono M., Une Y., Shirota K., Watanabe T. & Nomura Y. ( 1991 ) Canine renal carcinoma with extensive bone metastasis. The Journal of Veterinary Medical Science, 53: 495 – 7.en_US
dc.identifier.citedreferenceAtkins G. J., Bouralexis S., Haynes D. R., Graves S. E., Geary S. M., Evdokiou A., Zannettino A. C., Hay S. & Findlay D. M. ( 2001 ) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 28: 370 – 7.en_US
dc.identifier.citedreferenceAutzen P., Robson C. N., Bjartell A., Malcolm A. J., Johnson M. I., Neal D. E. & Hamdy F. C. ( 1998 ) Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. British Journal of Cancer, 78: 1219 – 23.en_US
dc.identifier.citedreferenceBarthez P. Y., Marks S. L., Woo J., Feldman E. C. & Matteucci M. ( 1997 ) Pheochromocytoma in dogs: 61 cases (1984–1995). Journal of Veterinary Internal Medicine, 11: 272 – 8.en_US
dc.identifier.citedreferenceBentley H., Hamdy F. C., Hart K. A., Seid J. M., Williams J. L., Johnstone D. & Russell R. G. ( 1992 ) Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. British Journal of Cancer, 66: 1159 – 63.en_US
dc.identifier.citedreferenceBoyce B. F., Yoneda T. & Guise T. A. ( 1999 ) Factors regulating the growth of metastatic cancer in bone. Endocrine-Related Cancer, 6: 333 – 47.en_US
dc.identifier.citedreferenceCase M. T., Bartz A. R., Bernstein M. & Rosen R. A. ( 1969 ) Metastasis of a sebaceous gland carcinoma in the dog. Journal of the Veterinary Medical Association, 154: 661 – 4.en_US
dc.identifier.citedreferenceChiao J. W., Moonga B. S., Yang Y. M., Kancherla R., Mittelman A., Wu-Wong J. R. & Ahmed T. ( 2000 ) Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. British Journal of Cancer, 83: 360 – 5.en_US
dc.identifier.citedreferenceCooley D. M. & Waters D. J. ( 1998 ) Skeletal metastasis as the initial clinical manifestation of metastatic carcinoma in 19 dogs. Journal of Veterinary Internal Medicine, 12: 288 – 93.en_US
dc.identifier.citedreferenceCooper C. R., Chay C. H., Gendernalik J. D., Lee H. L., Bhatia J., Taichman R. S., McCauley L. K., Keller E. T. & Pienta K. J. ( 2003 ) Stromal factors involved in prostate carcinoma metastasis to bone. Cancer, 97: 739 – 47.en_US
dc.identifier.citedreferenceCornell K. K., Bostwick D. G., Cooley D. M., Hall G., Harvey H. J., Hendrick M. J., Pauli B. U., Render J. A., Stoica G., Sweet D. C. & Waters D. J. ( 2000 ) Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate, 45: 173 – 83.en_US
dc.identifier.citedreferenceCornish J., Callon K. E., Lin C., Xiao C., Moseley J. M. & Reid I. R. ( 1999 ) Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. Journal of Bone and Mineral Research, 14: 915 – 22.en_US
dc.identifier.citedreferenceDeftos L. J. ( 2000 ) Prostate carcinoma: production of bioactive factors. Cancer, 88: 3002 – 8.en_US
dc.identifier.citedreferenceDurham S. K. & Dietze A. E. ( 1986 ) Prostatic adenocarcinoma with and without metastasis to bone in dogs. Journal of the Veterinary Medical Association, 188: 1432 – 6.en_US
dc.identifier.citedreferenceGilson S. D. ( 1998 ) Principles of surgery for cancer palliation and treatment of metastases. Clinical Techniques in Small Animal Practice, 13: 65 – 9.en_US
dc.identifier.citedreferenceGoltzman D., Karaplis A. C., Kremer R. & Rabbani S. A. ( 2000 ) Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer, 88: 2903 – 8.en_US
dc.identifier.citedreferenceGreen J. R. ( 2002 ) Bisphosphonates in cancer therapy. Current Opinion in Oncology, 14: 609 – 15.en_US
dc.identifier.citedreferenceGuise T. A. ( 2000 ) Molecular mechanisms of osteolytic bone metastases. Cancer, 88: 2892 – 8.en_US
dc.identifier.citedreferenceGuise T. A., Yin J. J., Taylor S. D., Kumagai Y., Dallas M., Boyce B. F., Yoneda T. & Mundy G. R. ( 1996 ) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. The Journal of Clinical Investigation, 98: 1544 – 9.en_US
dc.identifier.citedreferenceHan J. H., Choi S. J., Kurihara N., Koide M., Oba Y. & Roodman G. D. ( 2001 ) Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand. Blood, 97: 3349 – 53.en_US
dc.identifier.citedreferenceHarris S. E., Harris M. A., Mahy P., Wozney J., Feng J. Q. & Mundy G. R. ( 1994 ) Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate, 24: 204 – 11.en_US
dc.identifier.citedreferenceHoffman R. M. ( 2001 ) Visualization of GFP-expressing tumors and metastasis in vivo. Biotechniques, 30: 24 – 6.en_US
dc.identifier.citedreferenceHonore P., Luger N. M., Sabino M. A., Schwei M. J., Rogers S. D., Mach D. B., O'Keefe F., Ramnaraine P.,, M. L., Clohisy D. R. & Mantyh P. W. ( 2000 ) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Medicine, 6: 521 – 8.en_US
dc.identifier.citedreferenceHuang M. S., Wang T. J., Liang C. L., Huang H. M., Yang I. C., Yi-Jan H. & Hsiao M. ( 2002 ) Establishment of fluorescent lung carcinoma metastasis model and its real-time microscopic detection in SCID mice. Clinical & Experimental Metastasis, 19: 359 – 68.en_US
dc.identifier.citedreferenceHullinger T. G., Taichman R. S., Linseman D. A. & Somerman M. J. ( 2000 ) Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. Journal of Cellular Biochemistry, 78: 607 – 16.en_US
dc.identifier.citedreferenceJonsson L. & Gustafsson P. O. ( 1973 ) Bone-metastasizing squamous-cell carcinoma of the skin in a dog. The Journal of Small Animal Practice, 14: 159 – 65.en_US
dc.identifier.citedreferenceKaraplis A. C. & Vautour L. ( 1997 ) Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development. Current Opinion in Nephrology and Hypertension, 6: 308 – 13.en_US
dc.identifier.citedreferenceKeller E. T., Zhang J., Cooper C. R., Smith P. C., McCauley L. K., Pienta K. J. & Taichman R. S. ( 2001 ) Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer and Metastasis Reviews, 20: 333 – 49.en_US
dc.identifier.citedreferenceKillian C. S., Corral D. A., Kawinski E. & Constantine R. I. ( 1993 ) Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochemical and Biophysical Research Communications, 192: 940 – 7.en_US
dc.identifier.citedreferenceLacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y. X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J. & Boyle W. J. ( 1998 ) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165 – 76.en_US
dc.identifier.citedreferenceLaitinen M., Marttinen A., Aho A. J. & Lindholm T. S. ( 1998 ) Bone morphogenetic protein in bone neoplasms: comparison of different detection methods. European Surgical Research, 30: 168 – 74.en_US
dc.identifier.citedreferenceLe Brun G., Aubin P., Soliman H., Ropiquet F., Villette J. M., Berthon P., Creminon C., Cussenot O. & Fiet J. ( 1999 ) Upregulation of endothelin 1 and its precursor by IL-1β, TNF-α, and TGF-β in the PC3 human prostate cancer cell line. Cytokine, 11: 157 – 62.en_US
dc.identifier.citedreferenceLee-Parritz D. E. & Lamb C. R. ( 1988 ) Prostatic adenocarcinoma with osseous metastases in a dog. Journal of the Veterinary Medical Association, 192: 1569 – 72.en_US
dc.identifier.citedreferenceLeRoy B. E., Bahnson R. R. & Rosol T. J. ( 2002 ) New bone formation in nude mouse calvaria induced by canine prostate tissue. Molecular and Cellular Endocrinology, 197: 257 – 63.en_US
dc.identifier.citedreferenceLester P. & Gaynor J. S. ( 2000 ) Management of cancer pain. The Veterinary Clinics of North America. Small Animal Practice, 30: 951 – 66.en_US
dc.identifier.citedreferenceMichigami T., Ihara-Watanabe M., Yamazaki M. & Ozono K. ( 2001 ) Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Research, 61: 1637 – 44.en_US
dc.identifier.citedreferenceMirra J. M., Picci P. & Gold R. H. ( 1989 ) Bone Tumors: Clinical, Radiologic, and Pathologic Correlations. Philadelphia, Lea & Febiger, Philadelphia, PA.en_US
dc.identifier.citedreferenceMisdorp W. & den Herder B. A. ( 1966 ) Bone metastasis in mammary cancer. A report of 10 cases in the female dog and some comparison with human cases. British Journal of Cancer, 20: 496 – 503.en_US
dc.identifier.citedreferenceMontgomery D. L., Bendele R. & Storts R. W. ( 1980 ) Malignant aortic body tumor with metastasis to bone in a dog. Veterinary Pathology, 17: 241 – 4.en_US
dc.identifier.citedreferenceMundy G. R. ( 1997 ) Mechanisms of bone metastasis. Cancer, 80: 1546 – 56.en_US
dc.identifier.citedreferenceNelson J. B. & Carducci M. A. ( 2000 ) The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU International, 85: 45 – 8.en_US
dc.identifier.citedreferenceNelson J. B., Hedican S. P., George D. J., Reddi A. H., Piantadosi S., Eisenberger M. A. & Simons J. W. ( 1995 ) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Medicine, 1: 944 – 9.en_US
dc.identifier.citedreferenceNemeth J. A., Harb J. F., Barroso U. Jr, He Z., Grignon D. J. & Cher M. L. ( 1999 ) Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Research, 59: 1987 – 93.en_US
dc.identifier.citedreferencePadovan D., Yang T. J. & Fenton M. A. ( 1987 ) Epidural spinal metastasis of canine transmissible venereal sarcoma. Zentralblatt fur Veterinarmedizin A, 34: 401 – 4.en_US
dc.identifier.citedreferencePerkel V. S., Mohan S., Baylink D. J. & Linkhart T. A. ( 1990 ) An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP. The Journal of Clinical Endocrinology and Metabolism, 71: 533 – 5.en_US
dc.identifier.citedreferencePirtskhalaishvili G. & Nelson J. B. ( 2000 ) Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate, 44: 77 – 87.en_US
dc.identifier.citedreferenceRabbani S. A., Gladu J., Mazar A. P., Henkin J. & Goltzman D. ( 1997 ) Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. Journal of Cellular Physiology, 172: 137 – 45.en_US
dc.identifier.citedreferenceRamirez O. III, Dodge R. K., Page R. L., Price G. S., Hauck M. L., LaDue T. A., Nutter F. & Thrall D. E. ( 1999 ) Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Veterinary Radiology & Ultrasound, 40: 517 – 22.en_US
dc.identifier.citedreferenceRaval P., Hsu H. H., Schneider D. J., Sarras M. P. Jr, Masuhara K., Bonewald L. F. & Anderson H. C. ( 1996 ) Expression of bone morphogenetic proteins by osteoinductive and non-osteoinductive human osteosarcoma cells. Journal of Dental Research, 75: 1518 – 23.en_US
dc.identifier.citedreferenceReddi A. H., Roodman D., Freeman C. & Mohla S. ( 2003 ) Mechanisms of tumor metastasis to the bone: challenges and opportunities. Journal of Bone and Mineral Research, 18: 190 – 4.en_US
dc.identifier.citedreferenceRoodman G. D. ( 1996 ) Advances in bone biology: The osteoclast. Endocrine Reviews, 17: 308 – 32.en_US
dc.identifier.citedreferenceRoodman G. D. ( 1999 ) Cell biology of the osteoclast. Experimental Hematology, 27: 1229 – 41.en_US
dc.identifier.citedreferenceRovesti G. L., Guandalini A. & Peiffer R. ( 2001 ) Suspected latent vertebral metastasis of uveal melanoma in a dog: a case report. Veterinary Ophthalmology, 4: 75 – 7.en_US
dc.identifier.citedreferenceSasaki A., Boyce B. F., Story B., Wright K. R., Chapman M., Boyce R., Mundy G. R. & Yoneda T. ( 1995 ) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research, 55: 3551 – 7.en_US
dc.identifier.citedreferenceSerafini A. N. ( 2001 ) Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. The Quarterly Journal of Nuclear Medicine, 45: 91 – 9.en_US
dc.identifier.citedreferenceSiegel S. & Cronin K. L. ( 1997 ) Palliative radiotherapy. Veterinary Clinics of North America Small Animal Practice, 27: 149 – 55.en_US
dc.identifier.citedreferenceSimonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Luthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H. L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Pattison W., Campbell P. & Boyle W. J. ( 1997 ) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89: 309 – 19.en_US
dc.identifier.citedreferenceSmith D. A. & Hill F. W. ( 1989 ) Metastatic malignant mesothelioma in a dog. Journal of Comparative Pathology, 100: 97 – 101.en_US
dc.identifier.citedreferenceStowater J. L. ( 1979 ) Pheochromocytoma metastatic to bone in a dog. Veterinary Medicine Small Animal Clinics, 74: 343 – 6.en_US
dc.identifier.citedreferenceSzczech G. M., Blevins W. E., Carlton W. W. & Cutlan G. R. ( 1973 ) Chemodectoma with metastasis to bone in a dog. Journal of the Veterinary Medical Association, 162: 376 – 8.en_US
dc.identifier.citedreferenceTaguchi Y., Yamamoto M., Yamate T., Lin S. C., Mocharla H., DeTogni P., Nakayama N., Boyce B. F., Abe E. & Manolagas S. C. ( 1998 ) Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proceedings of the Association of American Physicians, 110: 559 – 74.en_US
dc.identifier.citedreferenceTerrell S. P., Platt S. R., Chrisman C. L., Homer B. L., de Lahunta A. & Summers B. A. ( 2000 ) Possible intraspinal metastasis of a canine spinal cord nephroblastoma. Veterinary Pathology, 37: 94 – 7.en_US
dc.identifier.citedreferenceThomas R. J., Guise T. A., Yin J. J., Elliott J., Horwood N. J., Martin T. J. & Gillespie M. T. ( 1999 ) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 140: 4451 – 8.en_US
dc.identifier.citedreferenceWlodarski K. & Reddi A. H. ( 1987 ) Tumor cells stimulate in vivo periosteal bone formation. Bone and Mineral, 2: 185 – 92.en_US
dc.identifier.citedreferenceYasuda H., Shima N., Nakagawa N., Mochizuki S. I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T. & Higashio K. ( 1998 ) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 139: 1329 – 37.en_US
dc.identifier.citedreferenceYin J. J., Selander K., Chirgwin J. M., Dallas M., Grubbs B. G., Wieser R., Massague J., Mundy G. R. & Guise T. A. ( 1999 ) TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. The Journal of Clinical Investigation, 103: 197 – 206.en_US
dc.identifier.citedreferenceYoneda T. ( 1998 ) Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. European Journal of Cancer, 34: 240 – 5.en_US
dc.identifier.citedreferenceYonou H., Kanomata N., Goya M., Kamijo T., Yokose T., Hasebe T., Nagai K., Hatano T., Ogawa Y. & Ochiai A. ( 2003 ) Osteoprotegerin/Osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Research, 63: 2096 – 102.en_US
dc.identifier.citedreferenceZhang J., Dai J., Qi Y., Lin D. L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J. & Keller E. T. ( 2001a ) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. The Journal of Clinical Investigation, 107: 1235 – 44.en_US
dc.identifier.citedreferenceZhang W., Feng J. Q., Harris S. E., Contag P. R., Stevenson D. K. & Contag C. H. ( 2001b ) Rapid in vivo functional analysis of transgenes in mice using whole body imaging of luciferase expression. Transgenic Research, 10: 423 – 34.en_US
dc.identifier.citedreferenceZhau H. E., Li C. L. & Chung L. W. ( 2000 ) Establishment of human prostate carcinoma skeletal metastasis models. Cancer, 88: 2995 – 3001.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1476-5829.2003.00023.x.pdf
Size:
1.615MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.